Malaysia is set to become a Hepatitis C treatment hub for the region. This was officially announced at Expo 2020 Dubai. The launch, held in conjunction with Malaysia Healthcare Excellence week from 3rd – 8th January 2022, was attended by industry players Thomson Hospital Kota Damansara, TMC Fertility and Women’s Specialist Centre, DoctorOnCall as well as Pharmaniaga, Malaysia’s largest pharmaceutical company.
Using a combination treatment of Ravidasvir and Sofosbuvir, Malaysia will be offering treatment for Hepatitis C with a cure rate of 97% and a cost reduction of 95%. This is in line with the World Health Organization’s (WHO) mission to reduce new viral Hepatitis infections by 90% and reduce deaths by viral Hepatitis by 65% by 2030.
Known for delivering world-class quality healthcare services which are both easily accessible and competitively affordable, Malaysia is fortifying its healthcare offerings through positioning itself as Fertility and Cardiology Hubs of Asia, Cancer Care Centre of Excellence and Hepatitis C Treatment Hub of Asia.
“This initiative is part of our recovery plans for the healthcare travel industry in Malaysia. We aim to become the global focal point for Hepatitis C treatment. In response to the World Hepatitis Day 2021 themed, “Hepatitis Can’t Wait”, Malaysia is ready and raring to move forward with a treatment solution for those infected with the disease,” said the Chief Executive Officer of Malaysia Healthcare Travel Council (MHTC), Mohd Daud Mohd Arif.
Malaysia has been recognised as the “Destination of the Year” by the International Medical Travel Journal (IMTJ) for four years (2015, 2016, 2017, and 2020) and the “Best Country in the World for Healthcare” based on International Living’s Global Retirement Index from 2015 to 2021.
Join our Telegram channel to receive latest news alert